A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Trial Profile

A Phase 3, Multicenter, Randomized, Double-blind, Active Controlled Study to Evaluate the Efficacy + Safety of IV + Oral Delafloxacin Compared With Vancomycin + Aztreonam in Patients With Acute Bacterial Skin and Skin Structure Infections (ABSSSI)

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Sep 2017

At a glance

  • Drugs Delafloxacin (Primary) ; Delafloxacin (Primary) ; Aztreonam; Vancomycin
  • Indications Bacterial infections; Skin and soft tissue infections
  • Focus Registrational; Therapeutic Use
  • Acronyms PROCEED
  • Sponsors Melinta Therapeutics
  • Most Recent Events

    • 25 Sep 2017 According to a Melinta Therapeutics media release, data will be presented at upcoming IDWeek 2017 annual scientific meeting.
    • 18 Sep 2017 According to a Melinta Therapeutics media release, an analysis of delafloxacin activity against fluoroquinolone-susceptible and fluoroquinolone-resistant Staphylococcus aureus isolates from individuals who had participated in PROCEED clinical trials was published in the journal Antimicrobial Agents and Chemotherapy.
    • 18 Sep 2017 Results from an analysis of delafloxacin activity against fluoroquinolone-susceptible and fluoroquinolone-resistant Staphylococcus aureus isolates from individuals who had participated in PROCEED clinical trials published in a Melinta Therapeutics media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top